Poplar Forest Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Poplar Forest Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-62,800	Closed	-$1.04M	–	71
2016 Q1	$1.04M	Buy	62,800 +42,000	+202%	+$735K	0.09%	48
2015 Q4	$451K	Buy	+20,800	New	+$405K	0.04%	68

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Poplar Forest Capital's HZNP Position: Q2 2016 in Review

Poplar Forest Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2016, closing a stake of 62,800 shares — an estimated $1.04M sold.

Poplar Forest Capital first reported a position in HZNP in Q4 2015 and held it in 2 quarters. The position peaked at $1.04M in Q1 2016. 198 funds tracked by Wall St. Rank hold HZNP as of Q2 2016.

Poplar Forest Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2016 after selling out during the quarter.
Poplar Forest Capital sold 62,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2016, an estimated $1.04M.
Poplar Forest Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 2 quarters.
Poplar Forest Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.04M in Q1 2016.
198 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2016.

Based on Poplar Forest Capital's 13F filing for Q2 2016, filed 12 Aug 2016.